Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted cancer drug discovery faces challenges like drug resistance, side effects, and non-specific activation.
• Recent FDA rejections highlight complexities in targeting receptors such as epidermal growth factor receptor (EGFR) and Insulin-like growth factor receptor 1 (IGF 1R) in metastatic cancers.
• EGFR and IGF 1R pathways are crucial in cancer and exhibit structural homology and functional crosstalk.

Purpose of the Study:

• To explore the potential of co-targeting EGFR and IGF 1R pathways for improved cancer therapy.
• To address the limitations of current targeted therapies by investigating combination or co-targeting strategies.
• To identify novel therapeutic approaches for patients with aberrantly activated EGFR and IGF 1R signaling.

Main Methods:

• Review of signaling pathways involving EGFR and IGF 1R.
• Analysis of structural homology and functional crosstalk between EGFR and IGF 1R families.
• Evaluation of therapeutic strategies including monoclonal antibodies and small molecule tyrosine kinase inhibitors.

Main Results:

• Aberrant activation of EGFR and IGF 1R pathways is common in many cancers.
• Structural and functional similarities suggest potential for combined targeting.
• Co-targeting or combination therapy may offer a promising new therapeutic avenue.

Conclusions:

• Simultaneous targeting of EGFR and IGF 1R presents a promising strategy to overcome current therapeutic barriers.
• Combination or co-targeting approaches with antibodies and inhibitors could lead to significant advancements in cancer treatment.
• This strategy may offer a new era of effective cancer therapy for patients with activated EGFR/IGF 1R pathways.